Dublin /PRNewswire/ - Endo International plc (NASDAQ: ENDP) today announced that data regarding the evaluation and rating of cellulite severity will be presented at the Annual Meeting of the American Society for Dermatologic Surgery (ASDS) in Phoenix, AZ. Two posters will be on display October 11th – October 13th: the first, an analysis of the Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS) for evaluating cellulite severity; and the second, an analysis of the potential impact of the gender of a healthcare provider (HCP) on rating cellulite severity.
One of the two abstract posters to be presented is titled "Assessing Cellulite Severity: Test-Retest Reliability of and Concordance between New Clinician Reported and Patient Reported Photonumeric Scales" and covers the 5-point photonumeric scales that measure cellulite severity according to the number and depth of dimples on the evaluated area. Results indicate that the CR-PCSS is a reliable tool for evaluating cellulite severity of the buttocks and thighs and correlates well with the Patient Reported Photonumeric Cellulite Severity Scale. This data was previously presented at the 2018 International Society for Pharmacoeconomics and Outcomes Research meeting.
The second abstract poster, titled "Analysis of Potential Impact of Healthcare Provider Gender on Rating Cellulite Severity," evaluates the influence of gender on healthcare providers' perception of cellulite severity. The HCPs rated female cellulite severity by viewing a set of digital images that represented the range of cellulite severity on buttocks or thighs. The results indicate that the gender of a HCP does not appear to impact assessment of cellulite severity ratings.
"We are pleased that the data from these studies will be presented at the premier meeting for dermatologic surgeons," said Matthew Davis, M.D., R.Ph., Chief Medical Officer, Senior Vice President, Research and Development, Branded Pharmaceuticals of Endo Pharmaceuticals. "It is important that healthcare providers and their patients have a reliable tool for evaluating cellulite severity. We believe the 5-point photonumeric scales enable patients and the clinician treating their cellulite to be aligned during both the informed consent process prior to treatment, and post treatment when they are evaluating the outcomes."
About the American Society for Dermatologic Surgery (ASDS)
The American Society for Dermatologic Surgery (ASDS) is the largest specialty organization exclusively representing dermatologic surgeons who have unique training and experience to treat the health, function and beauty of your skin. ASDS members are pioneers in the field. Many are involved in the clinical studies that bring popular treatments to revitalize skin and fill and diminish wrinkles to the forefront. Their work has helped create and enhance many of the devices that remove blemishes, hair and fat, and tighten skin. Dermatologic surgeons also are experts in skin cancer prevention, detection and treatment. As the incidence of skin cancer rises, dermatologic surgeons are committed to taking steps to minimize the life-threatening effects of this disease. For more information, visit asds.net.
Cellulite is a localized metabolic disorder of tissue under the skin that has been reported in 85 to 98 percent of post-pubertal females and affects women of all races and ethnicities[i] [ii]. The condition can involve the loss of elasticity or shrinking of collagen cords, called "septae," that attach the skin to the muscle layers below. When fat in cellulite-prone areas swells and expands, the septae tether the skin, which causes the surface dimpling characteristic of cellulite[iii]. Despite multiple therapeutic approaches for the attempted treatment of cellulite, there are no FDA-approved pharmacological treatments and little scientific evidence that any current treatments are beneficial[iv].
About Endo International plc
Endo International plc (NASDAQ: ENDP) is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more at www.endo.com.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and Canadian securities legislation, including, but not limited to, the statements by Dr. Davis, and other statements regarding research and development outcomes, efficacy, adverse reactions, market and product potential and product availability. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties. Although Endo believes that these forward-looking statements and information are based upon reasonable assumptions and expectations, readers should not place undue reliance on them, or any other forward-looking statements or information in this news release. Investors should note that many factors, as more fully described in the documents filed by Endo with the Securities and Exchange Commission and with securities regulators in Canada on the System for Electronic Document Analysis and Retrieval, including under the caption "Risk Factors" in Endo's Form 10-K, Form 10-Q and Form 8-K filings, and as otherwise enumerated herein or therein, could affect Endo's future results and could cause Endo's actual results to differ materially from those expressed in forward-looking statements contained in this communication. The forward-looking statements in this press release are qualified by these risk factors. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws.
[i] Avram, Cellulite: a review of its physiology and treatment, Journal of Cosmetic Laser Therapy 2004; 6: 181–185.
[ii] Khan MH et al. Treatment of cellulite: Part I. Pathophysiology. J Am Acad Dermatol. 2010 Mar;62(3):361-70.
[iii] Querleux, Anatomy and physiology of subcutaneous adipose tissue by in vivo MRI and spectroscopy: Relationship with sex and presence of cellulite, Skin Research and Technology; 8: 118-124.
[iv] Wanner M et al. An evidence-based assessment of treatments for cellulite. J Drugs Dermatol. 2008 Apr;7(4):341-5.
SOURCE: Endo International plcCopyright 2018 PR Newswire. All Rights Reserved